These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 27093896)

  • 1. Tibolone-induced acute hepatitis: Well-known drug, little-known complication.
    Macedo G; Silva M; Vilas-Boas F; Lopes S; Peixoto A; Carneiro F
    Gastroenterol Hepatol; 2017 Apr; 40(4):298-300. PubMed ID: 27093896
    [No Abstract]   [Full Text] [Related]  

  • 2. [Tibolone-induced hepatotoxicity].
    Blanco Sampascual S; de Las Heras Niño B; Cabezudo Gil P; Ruiz Eguiluz P; Orive Cura V
    Gastroenterol Hepatol; 2002 Apr; 25(4):274. PubMed ID: 11975880
    [No Abstract]   [Full Text] [Related]  

  • 3. Tibolone.
    Reynir Tomas G
    Acta Obstet Gynecol Scand; 2004 Jun; 83(6):606. PubMed ID: 15144349
    [No Abstract]   [Full Text] [Related]  

  • 4. What have we really learned from 'LIBERATE' trial?
    Dimitrakakis C; Tsigginou A; Keramopoulos D; Antsaklis A
    Maturitas; 2010 May; 66(1):99-100. PubMed ID: 20236777
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Does tibolone exacerbate atherosclerosis?
    Clarkson TB
    Eur Heart J; 2006 Mar; 27(6):635-7. PubMed ID: 16415302
    [No Abstract]   [Full Text] [Related]  

  • 6. A case report of recurrent endometriosis following Tibolone hormone replacement therapy.
    Sundar SS; Gornall RJ; Kerr-Wilson R; Swingler GR; Kinder RB; McCarthy K
    J Obstet Gynaecol; 2007 May; 27(4):433-4. PubMed ID: 17654209
    [No Abstract]   [Full Text] [Related]  

  • 7. Endometrial adenocarcinoma after prolonged tibolone therapy.
    Nassar AH; Khalil AM; Seoud MA; Usta IM
    Int J Gynaecol Obstet; 2005 Jul; 90(1):78-9. PubMed ID: 15913616
    [No Abstract]   [Full Text] [Related]  

  • 8. Effects of tibolone and continuous combined conjugated equine estrogen/medroxyprogesterone acetate on the endometrium and vaginal bleeding: results of the OPAL study.
    Langer RD; Landgren BM; Rymer J; Helmond FA;
    Am J Obstet Gynecol; 2006 Nov; 195(5):1320-7. PubMed ID: 16875644
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tibolone and breast cancer risk: effects of selection bias cannot be eliminated in observational studies.
    Coomarasamy A
    BJOG; 2008 Jun; 115(7):919. PubMed ID: 18485174
    [No Abstract]   [Full Text] [Related]  

  • 10. [Reasons for abandonment of hormone replacement therapy with tibolone in menopausal women].
    Zayas-Jaime FJ; Ornelas-Aguirre JM; Pérez-Nápoles DE
    Ginecol Obstet Mex; 2013 Oct; 81(10):593-601. PubMed ID: 24483042
    [TBL] [Abstract][Full Text] [Related]  

  • 11. By the way, doctor. What happened to tibolone--the estrogen alternative we heard about a while ago? Did it turn out not to be effective?
    Robb-Nicholson C
    Harv Womens Health Watch; 2004 Apr; 11(8):8. PubMed ID: 15100062
    [No Abstract]   [Full Text] [Related]  

  • 12. Carcinoma of the endometrium in patients treated with tibolone.
    Yazigi R; Sahid S; Contreras L; Rodriguez T
    Gynecol Oncol; 2004 May; 93(2):568-70. PubMed ID: 15099984
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Visceral adiposity after tibolone use.
    Carranza-Lira S; Bárcena-Jacobo TD; Sandoval-Barragán MP; Ramos-León JC
    Int J Gynaecol Obstet; 2011 Nov; 115(2):191-3. PubMed ID: 21872859
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tibolone: clinical recommendations and practical guidelines. A report of the International Tibolone Consensus Group.
    Kenemans P; Speroff L;
    Maturitas; 2005 May; 51(1):21-8. PubMed ID: 15883105
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tibolone reduces osteoporotic fracture risk and breast cancer risk, but increases the risk of stroke.
    de Melo NR; Pompei LM
    Gynecol Endocrinol; 2010 Feb; 26(2):73-5. PubMed ID: 19995151
    [No Abstract]   [Full Text] [Related]  

  • 16. Tibolone and risk of endometrial polyps: a prospective, comparative study with hormone therapy.
    Perez-Medina T; Bajo-Arenas J; Haya J; Sanfrutos L; Iniesta S; Bueno B; Castelo-Branco C
    Menopause; 2003; 10(6):534-7. PubMed ID: 14627862
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The LIBERATE tibolone trial in breast cancer survivors.
    Speroff L
    Maturitas; 2009 May; 63(1):1-3. PubMed ID: 19327923
    [No Abstract]   [Full Text] [Related]  

  • 18. Tibolone in postmenopausal women: a review based on recent randomised controlled clinical trials.
    Biglia N; Maffei S; Lello S; Nappi RE
    Gynecol Endocrinol; 2010 Nov; 26(11):804-14. PubMed ID: 20586550
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of fenofibrate on HDL cholesterol and HDL particle concentration in postmenopausal women on tibolone therapy.
    Stuckey BG; Barrett PH; Wagner JM; Hampton RA; Chan DC; Brown SJ; Watts GF
    Clin Endocrinol (Oxf); 2010 Oct; 73(4):497-501. PubMed ID: 20560981
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tibolone: the way to beat many a postmenopausal ailments.
    Lazovic G; Radivojevic U; Marinkovic J
    Expert Opin Pharmacother; 2008 Apr; 9(6):1039-47. PubMed ID: 18377345
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.